ICAD Inc
NASDAQ:ICAD

Watchlist Manager
ICAD Inc Logo
ICAD Inc
NASDAQ:ICAD
Watchlist
Price: 1.685 USD -7.92% Market Closed
Market Cap: 44.7m USD
Have any thoughts about
ICAD Inc?
Write Note

ICAD Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ICAD Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
ICAD Inc
NASDAQ:ICAD
Revenue
$18.9m
CAGR 3-Years
-19%
CAGR 5-Years
-8%
CAGR 10-Years
-7%
Veeva Systems Inc
NYSE:VEEV
Revenue
$2.7B
CAGR 3-Years
15%
CAGR 5-Years
21%
CAGR 10-Years
25%
Inspire Medical Systems Inc
NYSE:INSP
Revenue
$755.6m
CAGR 3-Years
55%
CAGR 5-Years
60%
CAGR 10-Years
N/A
Doximity Inc
NYSE:DOCS
Revenue
$475.4m
CAGR 3-Years
32%
CAGR 5-Years
41%
CAGR 10-Years
N/A
Omnicell Inc
NASDAQ:OMCL
Revenue
$1.1B
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
10%
W
Waystar Holding Corp
NASDAQ:WAY
Revenue
$791m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

ICAD Inc
Glance View

Market Cap
44.4m USD
Industry
Health Care

iCAD, Inc. is a medical technology company, which engages in the provision cancer detection and therapy solutions. The company is headquartered in Nashua, New Hampshire and currently employs 136 full-time employees. The firm operates through two segments: Cancer Detection (Detection) and Cancer Therapy (Therapy). In the Detection segment, the Company’s solutions include advanced image analysis and workflow solutions enables healthcare professionals to serve patients by identifying pathologies and pinpointing the prevalent cancers earlier, and a comprehensive range of artificial intelligence and computer aided detection (CAD) systems and workflow solutions for two-dimension(2D) and third dimension (3D) mammography, magnetic resonance imaging (MRI) and computed tomography (CT). In the Therapy segment, the Company offers the Xoft System, an isotope-free cancer treatment platform technology. The Xoft System can be used for the treatment of early-stage breast cancer, endometrial cancer, cervical cancer and nonmelanoma skin cancer.

ICAD Intrinsic Value
1.674 USD
Overvaluation 1%
Intrinsic Value
Price

See Also

What is ICAD Inc's Revenue?
Revenue
18.9m USD

Based on the financial report for Sep 30, 2024, ICAD Inc's Revenue amounts to 18.9m USD.

What is ICAD Inc's Revenue growth rate?
Revenue CAGR 10Y
-7%

Over the last year, the Revenue growth was -1%. The average annual Revenue growth rates for ICAD Inc have been -19% over the past three years , -8% over the past five years , and -7% over the past ten years .

Back to Top